XHKG
3869
Market cap59mUSD
Sep 21, Last price
3.40HKD
Name
Hospital Corporation of China Ltd
Chart & performance
P/E
2.90
P/S
0.27
EPS
1.00
Div yield, %
—
Shrs. gr., 5y
7.80%
Rev. gr., 5y
29.80%
Revenues
1.47b
+1.99%
Net income
136m
P
CFO
159m
-25.06%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hospital Corporation of China Limited, an investment holding enterprise, primarily focuses on the administration and direct management of hospitals across the People's Republic of China. The company extends specialized management and consulting services to institutions like Yangsi Hospital, Cixi Hospital, and Jinhua Hospital, alongside providing comprehensive general medical care. Additionally, the firm is active in the wholesale distribution of pharmaceutical products. Established in 2014, Hospital Corporation of China Limited maintains its corporate headquarters in Beijing, PRC, and functions as a subsidiary of Vanguard Glory Limited.
Key people
Shuai Chen
Executive Chairman of the Board, Acting Chief Executive Officer · since 2020
Chief Financial Officer, Executive Director · since 2022
Yuanzhi Wu
Deputy General Manager · since 2021
Chengchuan Pu
Executive Director · since 2021
Yue Ding
Chief Quality Management Nursing Officer · since 2014
Xiaofeng Lang
Chief Company Development Officer · since 2020
Su Yang
Chief Performance Officer · since 2018
Lixin Zhang
Chief Supply Chain Management · since 2020
Wing Yan Ho
Company Secretary · since 2021
Hui Liu
Chief Legal Officer and Secretary to the Board · since 2020
Lu Liu
Non-Executive Director · since 2017
Nan Wang
Non-Executive Director · since 2017
Jinxue Dang
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2016
Xiangliang Zhou
Non-Executive Independent Director · since 2016
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||